Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC
Drs Armstrong and Manning review the safety and efficacy data from the ALSYMPCA trial of radium-223 in patients with mCRPC.
EP: 1.The Evolution of Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
EP: 2.Approved Treatment Options for Patients with mCRPC
EP: 3.Patient Profile: A 78-Year-Old Man with mCRPC
EP: 4.Treatment Approaches for Patients with mCRPC and Bone-Only Disease Progression After Radiotherapy
EP: 5.Patient Profile: A 72-Year-Old Man with mCRPC and Multiple Bone Metastases
Now Viewing
EP: 6.Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC
EP: 7.Considerations for Treatment Selection for Patients with Disease Progression on Radium-223
EP: 8.Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases
EP: 9.Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC
EP: 10.Closing Thoughts on the Future of mCRPC Treatment
Related Videos
Related Content
